By Business & Finance 
GSK, a British drugmaker with Irish locations in Dublin and Cork, recently beat Q4 earnings estimates. The company is our FDI of the Month January 2025.
GSK is a pharmaceutical and biotechnology company with branches worldwide. Its locations in Ireland include Dublin and Cork.
The company recently posted its Q4 earnings, which exceed its initial estimates. The British group also lifted its 2031 sales target to nearly $50 billion.
Performing particularly strong is its HIV and oncology portfolio, which offset a fall in sales of respiratory syncytial virus (RSV) and shingles shots.
CEO Emma Walmsley said: “We are increasing and prioritising R&D investment to promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV”.
GSK has operated in Ireland for almost 100 years. Its Dublin headquarters is home to its commercial business, and it currently produces a range of over 100 prescription medicines and vaccines to patients in Ireland.
The company’s Cork hub is home to its global support staff working in R&D, pharmaceuticals and vaccines functions. Its laboratory at Carrigtwohill industrial estate provides specialised analytical support to global manufacturing network and supply chain teams.
GSK expects revenue to grow between 3 per cent and 5 per cent in 2025.
